Keywords
thrombosis
prevention
enoxaparin
How to Cite
Abstract
Obesity is a known independent risk factor for deep vein thrombosis and venous thromboembolism (VTE). It is a prevalent condition and its incidence has raised in the last few years, therefore increasing the population at risk of having a venous thrombotic event. After a surgery, VTE is a major cause of preventable death and the effectiveness of thromboprophylaxis is clear. However, the best approach in obese surgical inpatients is not defined. It has been suggested that enoxaparin 40 mg/day is less efficient than 60 mg/day to achieve appropiate anti X activity in obese patients. It is not clear whether higher doses of enoxaparin would also be more effective in preventing VTE, and if this would increase bleeding rates in a clinically meaningful quantity. We conducted a retrospective study to evaluate the real world thromboprophylaxis strategies in obese major surgical inpatients, and to compare enoxaparin doses of 40 mg/day and 60 mg/day in terms of VTE and major bleeding rates.
References
2. Ministerio de Salud de la Nación INdEyC. Cuarta Encuesta Nacional de Factores de Riesgo. Buenos Aires;
2018.
3. Ageno W, Di Minno MND, Ay C, Jang MJ, Hansen J-B, Steffen LM et al. Association Between the Metabolic Syndrome, Its Individual Components, and Unprovoked Venous Thromboembolism: Results of a Patient-Level Meta-Analysis. Arteriosclerosis, Thrombosis and Vascular Biology. 2014;34(11):2478-85.
4. Lentz SR. Thrombosis in the setting of obesity or inflammatory bowel disease. Blood. 2016;128(20):2388-94.
5. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S-e77S.
6. Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obesity Surgery. 2008;18(2):162-6.
7. Miranda S, Le Cam-Duchez V, Benichou J, Donnadieu N, Barbay V, Le Besnerais M et al. Adjusted
value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study. Thrombosis Research. 2017;155:1-5.
8. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for
VTE prophylaxis in morbidly obese, medically-Ill patients. Thrombosis Research. 2010;125(3):220-3.
9. Borkgren-Okonek MJ, Hart RW, Pantano JE, Rantis PC, Guske PJ, Kane JM et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery. 2008;4(5):625-31.
10. Wang T-F, Milligan PE, Wong CA, Deal EN, Thoelke MS, Gage BF. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thrombosis and Haemostasis. 2014;111(1):88-93.
11. Scholten DJ, Hoedema RM, Scholten SE. A Comparison of Two Different Prophylactic Dose Regimens of
Low Molecular Weight Heparin in Bariatric Surgery. Obesity Surgery. 2002;12(1):19-24.
12. Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. 2010;251(2):344-50.
13. Heit, Cohen. Estimated Annual Number of Incident and Recurrent, Non-Fatal and Fatal Venous Thromboembolism (VTE) Events in the US. 2005;106(11):910.
14. Samama M, Verhille C, Darchy L, editors. Relation between weight, obesity and frequency of deep venous thrombosis after enoxaparin in orthopedic-surgery. Thrombosis and haemostasis. 1995.
15. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans. Diabetes. 2007;56(4):1010-3.
16. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg. 2003;90(5):547-8.
17. Egan G, Ensom MHH. Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review. The Canadian Journal of Hospital Pharmacy. 2015;68(1):33-47.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar